- Home
- SYBT vs IRON Comparison
SYBT vs IRON Comparison
Compare SYBT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- IRON
- Stock Information
- Founded
- SYBT 1904
- IRON 2017
- Country
- SYBT United States
- IRON United States
- Employees
- SYBT N/A
- IRON N/A
- Industry
- SYBT Major Banks
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- IRON Health Care
- Exchange
- SYBT Nasdaq
- IRON Nasdaq
- Market Cap
- SYBT 2.3B
- IRON 2.1B
- IPO Year
- SYBT N/A
- IRON N/A
- Fundamental
- Price
- SYBT $71.54
- IRON $63.05
- Analyst Decision
- SYBT Hold
- IRON Strong Buy
- Analyst Count
- SYBT 3
- IRON 10
- Target Price
- SYBT $83.67
- IRON $97.80
- AVG Volume (30 Days)
- SYBT 105.8K
- IRON 329.3K
- Earning Date
- SYBT 10-22-2025
- IRON 11-11-2025
- Dividend Yield
- SYBT 1.68%
- IRON N/A
- EPS Growth
- SYBT 22.18
- IRON N/A
- EPS
- SYBT 4.35
- IRON N/A
- Revenue
- SYBT $364,546,000.00
- IRON N/A
- Revenue This Year
- SYBT $16.83
- IRON N/A
- Revenue Next Year
- SYBT $5.12
- IRON N/A
- P/E Ratio
- SYBT $16.96
- IRON N/A
- Revenue Growth
- SYBT 11.32
- IRON N/A
- 52 Week Low
- SYBT $57.12
- IRON $30.82
- 52 Week High
- SYBT $83.83
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- SYBT 32.82
- IRON 61.41
- Support Level
- SYBT $73.70
- IRON $59.74
- Resistance Level
- SYBT $75.68
- IRON $62.98
- Average True Range (ATR)
- SYBT 2.08
- IRON 2.50
- MACD
- SYBT -0.67
- IRON 0.14
- Stochastic Oscillator
- SYBT 1.30
- IRON 67.63
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.